All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias confirmed Covid-19, from 1st dosedetailed results COVE Moderna/NIH phase 3 (study 301), 2020 0.05 [0.03; 0.09]
0.05 [0.03 ; 0.09 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 28,207 NA not evaluable deathsdetailed results COVE Moderna/NIH phase 3 (study 301), 2020 0.50 [0.02; 14.84]
0.50 [0.02 ; 14.84 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 28,207 NA not evaluable vaccine efficacy from randomization (ITT)detailed results COVE Moderna/NIH phase 3 (study 301), 2020 0.07 [0.04; 0.11]
0.07 [0.04 ; 0.11 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,148 NA not evaluable symptomatic Covid-19detailed results COVE Moderna/NIH phase 3 (study 301), 2020 0.06 [0.03; 0.11]
0.06 [0.03 ; 0.11 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 28,207 NA not evaluable severe COVID-19 occurrencedetailed results COVE Moderna/NIH phase 3 (study 301), 2020 0.02 [0.00; 0.27]
0.02 [0.00 ; 0.27 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 28,207 NA not evaluable serious adverse eventsdetailed results COVE Moderna/NIH phase 3 (study 301), 2020 1.04 [0.78; 1.40]
1.04 [0.78 ; 1.40 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable adverse eventsdetailed results COVE Moderna/NIH phase 3 (study 301), 2020 1.14 [1.08; 1.20]
1.14 [1.08 ; 1.20 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable appendicitisdetailed results COVE Moderna/NIH phase 3 (study 301), 2020 0.67 [0.11; 3.99]
0.67 [0.11 ; 3.99 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable arthralgia, grade 3-4detailed results COVE Moderna/NIH phase 3 (study 301), 2020 18.37 [13.54; 24.91]
18.37 [13.54 ; 24.91 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable Bell's palsydetailed results COVE Moderna/NIH phase 3 (study 301), 2020 3.00 [0.31; 28.83]
3.00 [0.31 ; 28.83 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable hypersensitivity, all termsdetailed results COVE Moderna/NIH phase 3 (study 301), 2020 1.41 [1.15; 1.72]
1.41 [1.15 ; 1.72 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable lymphadenopathy, grade 3-4detailed results COVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97]
1.00 [0.06 ; 15.97 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable musculoskeletal and connective tissue disorders, anydetailed results COVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97]
1.00 [0.06 ; 15.97 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable myalgia, grade 3-4detailed results COVE Moderna/NIH phase 3 (study 301), 2020 27.64 [20.93; 36.50]
27.64 [20.93 ; 36.50 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable fever, grade 3-4detailed results COVE Moderna/NIH phase 3 (study 301), 2020 43.29 [17.83; 105.10]
43.29 [17.83 ; 105.10 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,242 NA not evaluable local adverse reaction, any, dose 2detailed results COVE Moderna/NIH phase 3 (study 301), 2020 33.74 [31.59; 36.03]
33.74 [31.59 ; 36.03 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,235 NA not evaluable local adverse reaction, grade 3-4, dose 2detailed results COVE Moderna/NIH phase 3 (study 301), 2020 15.04 [11.83; 19.12]
15.04 [11.83 ; 19.12 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,235 NA not evaluable systemic adverse reaction, any, dose 2detailed results COVE Moderna/NIH phase 3 (study 301), 2020 6.69 [6.35; 7.05]
6.69 [6.35 ; 7.05 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,242 NA not evaluable systemic adverse reaction, grade 3-4, dose 2detailed results COVE Moderna/NIH phase 3 (study 301), 2020 9.50 [8.38; 10.77]
9.50 [8.38 ; 10.77 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,242 NA not evaluable 0.0 100.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-04 12:10 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 89
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290
